Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
912
Views
0
CrossRef citations to date
0
Altmetric
Urology

A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix in patients diagnosed with non-muscle-invasive bladder cancer in France

Jonathan BelseyJB Medical Ltd, London, UKCorrespondence[email protected]
Pages 1398-1406 | Received 28 Jul 2023, Accepted 04 Oct 2023, Published online: 28 Oct 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
  • WHO, International Agency for Research on Cancer. Factsheet: France (GLOBOCAN 2020). 2021. https://gco.iarc.fr/today/data/factsheets/populations/250-france-fact-sheets.pdf.
  • Cancer.Net. Bladder Cancer: statistics. 2023.
  • Zhai M, Tang C, Li M, et al. Short term mortality risks among patients with non-metastatic bladder cancer. BMC Cancer. 2020;20(1):1148. doi: 10.1186/s12885-020-07655-x.
  • Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37(3):219–225. doi: 10.1016/j.canep.2013.02.002.
  • Rouprêt M, Pignot G, Masson-Lecomte A, et al. Recommandations françaises du comité de cancérologie de l’AFU – actualisation 2020–2022: tumeurs de la vessie. Prog Urol. 2020;30(12S):S78–S135. doi: 10.1016/S1166-7087(20)30751-X.
  • Sylvester RJ, van der Meijden A, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–477. doi: 10.1016/j.eururo.2005.12.031.
  • Adiyat KT, Katkoori D, Soloway CT, et al. Complete transurethral resection of bladder tumor": are the guidelines being followed? Urology. 2010;75(2):365–367. doi: 10.1016/j.urology.2009.08.082.
  • Maisch P, Koziarz A, Vajgrt J, et al. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021;12(12):CD013776. ArtNoCD013776
  • Rouprêt M, Malavaud B, Molinier L, et al. Coût-efficacité de la resection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France. Prog Urol. 2015;25(5):256–264. doi: 10.1016/j.purol.2015.01.004.
  • Agence Technique de L’Information sur L’Hospitalisation. Tarifs MCO et HAD. https://www.atih.sante.fr/sites/default/files/public/content/1568/tarif_arrete_2023.xlsx.
  • ScanSanté. Analyse des coûts. 2019. https://www.scansante.fr/applications/enc-mco.
  • Russo G, Sholklapper T, Cocci A, et al. Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: a systematic review and lesion-level diagnostic meta-analysis. Cancers. 2021;13(17):4378. doi: 10.3390/cancers13174378.
  • Veeratterapillay R, Gravestock P, Nambiar A, et al. Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur Urol Open Sci. 2021;31:17–27. doi: 10.1016/j.euros.2021.06.011.
  • Das S, Gu L, Eve CT, et al. The impact of blue light cystoscopy use among nonmuscle invasive bladder cancer patients in an equal access setting: implications on recurrence and time to recurrence. Clin Genitourin Cancer. 2023;S1558-7673(23)00098-8. doi: 10.1016/j.clgc.2023.04.011.
  • Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862–866; discussion 866. doi: 10.1097/01.ju.0000169257.19841.2a.
  • Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171(1):135–138. doi: 10.1097/01.ju.0000100480.70769.0e.
  • Daneshmand S, Bazargani ST, Bivalacqua TJ, et al. Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry. Urol Oncol. 2018;36(8):361.e1–361.e6. doi: 10.1016/j.urolonc.2018.04.013.
  • Mowatt G, N'Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care. 2011;27(1):3–10. doi: 10.1017/S0266462310001364.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.